Spyre Therapeutics, Inc. Common Stock
SYRESpyre Therapeutics, Inc. (SYRE) is a biotechnology company focused on developing targeted therapies for immune-mediated diseases. The company leverages its proprietary technology platform to discover and advance novel biologics aimed at modulating immune responses, with the goal of treating conditions such as autoimmune disorders and inflammatory diseases.
Company News
Spyre Therapeutics presented scientific data on SPY072, a potential first-in-class anti-TL1A agent for rheumatic diseases, showcasing promising Phase 1 study results with potential quarterly or twice-yearly dosing and preclinical efficacy comparable to etanercept.
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday’s session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter. Analysts, on...
Spyre Therapeutics (SYRE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
